CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Please ensure you fully understand the risks involved. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Please ensure you fully understand the risks involved.

Weight loss

AU market earnings: ResMed's robust performance

ResMed reports a significant revenue rise of 9% to $1.22 billion USD in the June quarter, highlighting its strong market position despite concerns over weight loss drugs impacting product demand.

2024-08-05T08:13:42+0100

Macro Intelligence: weight-loss drugs drive big pharma

After an initial negative reaction to the weight-loss drug thematic, ResMed says the trend will boost demand for its products. However, with alcohol consumption amongst GLP-1 patients waning, beverage companies could suffer.

2024-05-08T01:11:19+0100

Macro Intelligence: Wegovy, Ozempic and Mounjaro transform obesity treatment and market dynamics

Explore how GLP-1 drugs like Wegovy, Ozempic, and Mounjaro are reshaping the obesity treatment landscape, boosting market valuations for Novo Nordisk and Eli Lilly, and influencing sectors from healthcare to consumer goods.

2023-11-15T00:54:27+0000

Contact us

Interested in opening an account?

Contact 1800 601 799 or newaccounts.au@ig.com

Want to check on your application’s progress?

Email newaccounts.au@ig.com

Have another question?

Browse our Help and Support portal

WhatsApp: Click here

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You do not own or have any interest in the underlying asset. You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money. Please consider the Margin Trading Product Disclosure Statement (PDS), Risk Disclosure Notice and Target Market Determination before entering into any CFD transaction with us.

The value of shares, ETFs and ETCs bought through an IG share trading account can fall as well as rise, which could mean getting back less than you originally put in. Past performance is no guarantee of future results.

Please ensure you fully understand the risks and take care to manage your exposure.

The information on this website is prepared without considering your objectives, financial situation or needs. Consequently, you should consider the information in light of your objectives, financial situation and needs.

This website is operated by IG Australia Pty Ltd. IG Australia Pty Ltd is located on Level 32, Queen & Collins, 376-390 Collins Street, Melbourne, VIC 3000. ABN 93 096 585 410, Australian Financial Services Licence No. 515106. Derivatives Issuer Licence in New Zealand FSP No. 684191, NZBN 9429047618251.

IG Group | Careers

Weight loss

Article result template

AU market earnings: ResMed's robust performance

Macro Intelligence: weight-loss drugs drive big pharma

Macro Intelligence: Wegovy, Ozempic and Mounjaro transform obesity treatment and market dynamics

Markets

Trading platforms

Analysis

About

Contact us